A 52-year-old man presents to his physician for routine follow-up. He emigrated from China 20 years ago and was diagnosed with chronic hepatitis B infection during a pre-employment physical examination. He feels well and denies abdominal pain, jaundice, weight loss, or gastrointestinal bleeding. Past medical history is otherwise negative. His medications include tenofovir, which he has taken consistently for the past 5 years. Recent laboratory studies show undetectable hepatitis B virus (HBV) DNA levels. Liver biopsy performed several years ago demonstrated mild fibrosis without cirrhosis.
Vital signs are normal. Physical examination is unremarkable.
Which of the following is the most appropriate recommendation regarding hepatocellular carcinoma surveillance?
The correct answer is:
A) Abdominal ultrasound every 6 months
This patient has chronic hepatitis B infection and remains at increased risk for hepatocellular carcinoma (HCC) despite effective antiviral therapy and the absence of cirrhosis. Unlike most other chronic liver diseases, hepatitis B can lead to HCC even before cirrhosis develops. Therefore, certain high-risk patients with chronic hepatitis B require routine HCC surveillance regardless of cirrhosis status.
A major Step 2 concept is that hepatitis B differs from hepatitis C, alcohol-associated liver disease, and many other chronic liver diseases because viral integration into the host genome can directly contribute to carcinogenesis. As a result, patients with chronic hepatitis B may develop HCC in the absence of advanced fibrosis or cirrhosis.
Risk factors that support surveillance include male sex, increasing age, Asian ancestry, African ancestry, family history of HCC, and longstanding infection. This patient is an Asian man older than 40 years with chronic hepatitis B, placing him in a surveillance group.
The preferred surveillance strategy is abdominal ultrasound every 6 months. The goal is to detect HCC at an early stage when potentially curative treatments remain possible.
This question intentionally contrasts with common screening paradigms in other liver diseases, where cirrhosis is usually the primary determinant of HCC surveillance eligibility.
Answer choice B: Colonoscopy every 10 years, is incorrect.
This may be appropriate for average-risk colorectal cancer screening, but it does not address this patient’s increased risk of hepatocellular carcinoma due to chronic hepatitis B infection.
Answer choice C: Discontinue surveillance because HBV DNA is undetectable, is incorrect.
Effective antiviral therapy substantially reduces the risk of HCC but does not eliminate it. Patients who meet surveillance criteria should continue surveillance despite virologic suppression.
Answer choice D: Serum alpha-fetoprotein testing every 5 years, is incorrect.
Alpha-fetoprotein (AFP) alone is not an adequate surveillance strategy, and a 5-year interval is far too infrequent to detect early-stage HCC reliably.
Answer choice E: Surveillance only after cirrhosis develops, is incorrect.
This is a common board trap. Unlike many chronic liver diseases, hepatitis B can cause HCC in the absence of cirrhosis. High-risk patients require surveillance before cirrhosis develops.
Key Learning Point
Chronic hepatitis B infection is unique among major chronic liver diseases because hepatocellular carcinoma can develop in the absence of cirrhosis. High-risk patients should undergo HCC surveillance with abdominal ultrasound every 6 months, even when antiviral therapy has successfully suppressed viral replication.
